Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504–7.
   PubMed Web of Science ®Google Scholar
• Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat Rev Microbiol 2013;11:115–28.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine 2015;33:D24–31.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195–206.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015;372:113–23.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine 2016;34:2934–8.
   PubMed Web of Science ®Google Scholar
• Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 2013;100:500–19.
   PubMed Web of Science ®Google Scholar
• Lim SP, Shi PY. West Nile virus drug discovery. Viruses 2013;5:2977–3006.
   PubMed Web of Science ®Google Scholar
• Luo D, Vasudevan SG, Lescar J. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antiviral Res 2015;118:148–58.
   PubMed Web of Science ®Google Scholar
• Nitsche C, Holloway S, Schirmeister T, Klein CD. Biochemistry and medicinal chemistry of the dengue virus protease. Chem Rev 2014;114:11348–81.
   PubMed Web of Science ®Google Scholar
• Steuber H, Kanitz M, Ehlert FR, Diederich W. Recent advances in targeting Dengue and West Nile virus proteases using small molecule inhibitors. In: Diederich WE, Steuber H, eds. Therapy of viral infections. Topics in medicinal chemistry. Vol. 15. Berlin, Heidelberg: Springer; 2015:93–141.
   Google Scholar
• Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem 2006;281:38448–58.
   PubMed Web of Science ®Google Scholar
• Shiryaev SA, Ratnikov BI, Aleshin AE, et al. Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol 2007;81:4501–9.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11:367–83.
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Murray CL, Thiel H-J, Rice CM. Chapter 25: Flaviviridae. In: David M, Knipe PMH, eds. Fields virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:712–46.
   Google Scholar
• Shiryaev SA, Ratnikov BI, Chekanov AV, et al. Cleavage targets and the d-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J 2006;393:503–11.
   PubMed Web of Science ®Google Scholar
• Lim HA, Joy J, Hill J, San Brian Chia C. Novel agmatine and agmatine-like peptidomimetic inhibitors of the West Nile virus NS2B/NS3 serine protease. Eur J Med Chem 2011;46:3130–4.
   PubMed Web of Science ®Google Scholar
• Lim HA, Ang MJ, Joy J, et al. Novel agmatine dipeptide inhibitors against the West Nile virus NS2B/NS3 protease: a P3 and N-cap optimization study. Eur J Med Chem 2013;62:199–205.
   PubMed Web of Science ®Google Scholar
• Hammamy MZ, Haase C, Hammami M, et al. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem 2013;8:231–41.
   PubMed Web of Science ®Google Scholar
• Weigel LF, Nitsche C, Graf D, et al. Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors. J Med Chem 2015;58:7719–33.
   PubMed Web of Science ®Google Scholar
• Saupe SM, Steinmetzer T. A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem 2012;55:1171–80.
   PubMed Web of Science ®Google Scholar
• Bernatowicz MS, Wu Y, Matsueda GR. Urethane protected derivatives of 1-guanylpyrazole for the mild and efficient preparation of guanidines. Tetrahedron Lett 1993;34:3389–92.
   Web of Science ®Google Scholar
• Elsawy MA, Hewage C, Walker B. Racemisation of N-Fmoc phenylglycine under mild microwave-SPPS and conventional stepwise SPPS conditions: attempts to develop strategies for overcoming this. J Pept Sci 2012;18:302–11.
   PubMed Web of Science ®Google Scholar
• Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012;287:21992–2003.
   PubMed Web of Science ®Google Scholar
• Hardes K, Becker GL, Lu Y, et al. Novel furin inhibitors with potent anti-infectious activity. ChemMedChem 2015;10:1218–31.
   PubMed Web of Science ®Google Scholar
• D’Arcy A, Chaillet M, Schiering N, et al. Purification and crystallization of dengue and West Nile virus NS2B-NS3 complexes. Acta Crystallogr F Struct Biol Cryst Commun 2006;62:157–62.
   PubMedGoogle Scholar
• Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170–1.
   PubMed Web of Science ®Google Scholar
• Nitsche C, Schreier VN, Behnam MA, et al. Thiazolidinone-peptide hybrids as Dengue Virus protease inhibitors with antiviral activity in cell culture. J Med Chem 2013;56:8389–403.
   PubMed Web of Science ®Google Scholar
• Stoermer MJ, Chappell KJ, Liebscher S, et al. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem 2008;51:5714–21.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Flaviviruses and their antigenic structure. J Clin Virol 2012;55:289–95.
   PubMed Web of Science ®Google Scholar
• Fuchs SM, Raines RT. Internalization of cationic peptides: the road less (or more?) traveled. Cell Mol Life Sci 2006;63:1819–22.
   PubMed Web of Science ®Google Scholar
• Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 2012;17:850–60.
   PubMed Web of Science ®Google Scholar
• Aleshin AE, Shiryaev SA, Strongin AY, Liddington RC. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 2007;16:795–806.
   PubMed Web of Science ®Google Scholar
• Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988;27:6517–22.
   PubMed Web of Science ®Google Scholar
• Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudin–thrombin complex. J Mol Biol 1991;221:583–601.
   PubMed Web of Science ®Google Scholar
• Samanta S, Lim TL, Lam Y. Synthesis in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsul fanyl}acetamide scaffold. ChemMedChem 2013;8:994–1001.
   PubMed Web of Science ®Google Scholar
• Gao Y, Samanta S, Cui T, Lam Y. Synthesis in vitro evaluation of West Nile virus protease inhibitors based on the 1,3,4,5-tetrasubstituted 1H-pyrrol-2(5H)-one scaffold. Chem Med Chem 2013;8:1554–60.
   Web of Science ®Google Scholar
• Wu H, Bock S, Snitko M, et al. Novel Dengue Virus NS2B/NS3 protease inhibitors. Antimicrob Agents Chemother 2015;59:1100–9.
   PubMed Web of Science ®Google Scholar
• Behnam MA, Nitsche C, Boldescu V, Klein CD. The medicinal chemistry of dengue virus. J Med Chem 2016;59:5622–49.
   PubMed Web of Science ®Google Scholar